TrialBlood advances2026

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

Guy Young et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.